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 Abstract - Monoclonal gammopathy of undetermined 
significance (MGUS) is a non malignant plasma cell disorder 
with a relatively low risk of progression to Multiple Myeloma 
(MM) and to related Plasma cells disordes 
(lymphoplasmacellular neoplasms, Waldenstrom 
Macroglobulinemia or light chain amyloidosis). It is a quite 
common finding, especially in the population above the age 
of 50 and it  can also present in association  with many non 
malignant conditions. Differential diagnosis of symptomatic 
and asymptomatic forms is the determinant for starting 
therapy. Over the last few years many advances in the 
understanding of the biology of MGUS, together with large 
epidemiological studies, allowed to define risk models to 
estimate the risk of progression to MM according to MGUS 
isotype and, more recently, to peculiar flow cytometry 
findings. The goal of many recent studies aims at evaluating 
individual patients and their overall risk of progression, the 
detection of early signs of progression and the development 
of timely treatment strategies. 
 
Keywords: MGUS, Monoclonal gammopathy of undetrmined 
significance, non malignant haematological disorders, pre-




I.  INTRODUCTION 
 
 Monoclonal gammopathy of undetermined 
significance (MGUS) is an asymptomatic plasma cell 
disorder; it is a non malignant common condition 
affecting at least 3% of the population above the age of 
50, with an average 1% annual risk of progression to 
Multiple Myeloma (MM) [1]. 
 A monoclonal gammopathy can be associated with 
many non malignant conditions, frequently observed in 
common clinical practice. 
MGUS virtually precedes the development of MM 
and related disorders:, lymphoplasmacellular neoplasms, 
Waldenstrom Macroglobulinemia or light chain 
amyloidosis [2,3]. 
Differential diagnosis of symptomatic and 
asymptomatic monoclonal gammopathies is the 
determinant for starting therapy [4]. 
Over the last few years, advances in the 
understanding of the pathogenesis of this disease and large 
epidemiological studies [5], allowed the design of risk 
models to estimate the individual risk of progression to 
MM. The development of individualized risk profiles, 
through the use of flow cytometry [6], free light chain 
analyses and risk models [5] represent an interesting 
ongoing challenge since the distinction of patients in low- 
and high-risk would allow a tailored clinical management 
of MGUS patients [7]. An early detection of the signs of 
progression could lead to the development of early 
treatment strategies. The aim of this report is to provide 
current information on the diagnosis, biology, risk 




II. DEFINITIONS AND CLINICAL ASPECTS 
 
 Most monoclonal proteins (M-proteins) are detected 
incidentally during routine checks, especially when 
investigating an increased erythrocyte sedimentation rate 
in older people. 
When a spike-like peak is first found on serum 
protein electrophoresis (SPEP), serum and urine 
immunefixation electrophoresis (IFE) should be 
performed additionally and the class specific 
immunoglobulins should be quantitatively determined to 
confirm the diagnosis of monoclonal gammopathy [8,9]. 
Quantitative measuring of free light chains in the serum is 
a new, highly sensitive, method that may be helpful in 
assessing the prognosis and controlling the course of the 
disease [5]. 
The typical laboratory investigations necessary to 
differentiate MGUS from other related plasma cell (PC) 
disorders are a complete blood cell count (CBC), serum 
creatinine measurement, serum calcium measurement, and 
a complete radiographic bone survey. 
Among B cells disorders, MGUS is, by definition, 
characterized by a serum M protein concentration of less 
than 30 g/L, fewer than 10% clonal PCs in the bone 
marrow, and the absence of end-organ damage defined by  
hypercalcemia, renal insufficiency, anemia, or bone 
lesions (CRAB) [10] (Table 1). A bone marrow aspirate 
and biopsy are required in case of abnormalities in the 
blood/urine tests, when the M protein level is greater than 
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TABLE I. DIAGNOSTIC CRITERIA FOR PLASMA CELL DISORDERS 
 
DISORDER DISEASE DEFINITION 
MGUS 
Serum monolonal protein level< 30 g/L, bone marrow plasma cells<10% and absence of end-organ damage, 
such as lytic bone lesions, hypercalcemia, or renal failure, that can be attributed to a plasmacell proliferative 
disorder. 
SMM (also referred to 
asymptomatic multiple myeloma) 
Serum monoclonal protein (IgG or IgA) level ≥30 g/L an or bone marrow plasma cells ≥10%, absence of end-
organ damage such as lytic bone lesions, hypercalcemia, or renal failure, that can be attributed to a plasmacell 
proliferative disorder. 
Multiple Myeloma Bone marrow plasma cells ≥10%, presence of serum and/or urinary monoclonal protein (except in patients with 
true nonsecretory multiple myeloma, plus evidence of lytic bone lesions, anemia, hypercalcemia, or renal 
failure, that can be attributed to the underlying  plasma cell proliferative disorder. 
Waldenström  Macroglobulinemia 
IgM monoclonal gammopathy (regardless of the size of the M protein) with > 10% bone marrow 
lymphoplasmacytic infiltration (usually intertrabecoular) by small lymphocytes that exhibit plasmacytoid or 
plasma cell differentiation and a typical immunophenotype (eg, surface IgM+, CD5+/-, CD10-, CD19+, 
CD20+,CD23-) that satisfactorily excludes other lymphoproliferative disorders, including chronic lymphocytic 
leukemia and mantle cell lymphoma. Note: IgM MGUS is defined is defined as a serum IgM  monoclonal 
protein level <30 g/L, bone marrow lymphoplasmocytic infiltration <10%, and no evidence of anemia, 
constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly. Smolderin Waldenström 
macroglobulinemia (also referred to as indolent or asymptomatic Waldenström  macroglobulinemia) is defined 
as serum IgM monoclonal protein level ≥30 g/L and/or bone marrow lymphoplasmocytic infiltration ≥10% and 
no evidence of end-organ damage, such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, 
or hepatosplenomegaly, that can be attributed to a plasma cell proliferative disorder. 
Solitary Plasmocitoma 
Biopsy-proven  solitary lesion of bone or soft tissue with evidence of  clonal plasma cells, normal bone marrow 
with no evidence of clonal plasma cells, normal skeletal survey and MRI of spine and pelvis, and absence of 
end-organ damage such as anemia, hypercalcemia, renal failure, that can be attributed to a plasma cell 
proliferative disorder. 
Systemic AL amyloidosis 
Presence of an amyloid-related systemic syndrome (such as renal, liver, heart, gastrointestinal tract, or 
peripheral nerve involvement) with positive amyloid staining by Congo red in any tissue (eg fat aspirate, bone 
marrow, or organ biopsy), plus evidence that amyloid is light chain related established by direct examination of 
the amyloid (immunoperoxidase staining, direct sequencing, etc) plus evidence of a monoclonal plasma cell 
proliferative disorder (serum or urine M protein, abnormal free light chain ratio, or clonal plasma cells in the 
bone marrow). 
POEMS 
Presence of a monoclonal plasma cell disorder, peripheral neuropathy, and at least one of the following 7 
features: osteosclerotic myeloma; Castleman disease, Organomegaly, endocrinopathy (excluding diabetes 
mellitus or hypothyroydism), edema, typical skin changes, and papilledema. 
Abbreviations. MGUS: monoclonal Gammopathy of undetermined significance; SMM: ; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, 
M (protein) and Skin changes. 
non-IgG MGUS, and/or an abnormal serum free light 
chain (FLC) ratio, and in any other patient with presumed 
MGUS in whom there is doubt about the diagnosis [11]. 
Large epidemiological and clinical studies have led Mayo 
Clinic investigators to define 3 distinct clinical subtypes 
of MGUS: non-IgM MGUS, by far the most common; 
IgM-MGUS; and light-chain MGUS [12], each with a 
different mode and cumulative risk of progression to MM 
at 10 years (Table 2). 
 
TABLE II. PROGNOSIS OF MGUS:  
TYPE OF M-SPIKE AND ABSOLUTE RISK OF 
PROGRESSION 
 
Serum M-Spike type 
Cumulative incidence of full 
progression at 10 years 
IgG 7% 
 IgA 13% 
 IgM 18% 
Source: see ref. 11.  
The most well-characterized subtype is non-IgM 
MGUS, in which the M-component isotype can be IgG 
(69%), IgA (11%), or biclonal (3%); IgD and IgE are rare 
[1]. 
Malignant transformation of non-IgM MGUS 
approximates 1% per year and typically develops into 
multiple myeloma rather than lymphoproliferative 
disorders (LPDs) [8]. 
IgM MGUS occurs in approximately 11% of patients 
[13], it has a predilection for developing Waldenstrom 
macroglobulinemia or other lymphomas while rarely 
progressing to IgM MM [14]. 
People with MGUS can occasionally present 
numbness or tingling in their hands and feet, or problems 
with their balance, due to peripheral nerves damage 
caused by paraproteinemia. 
This situation configures a disorder called 
Paraproteinaemic Demyelinating Neuropathy (PDN) or 
MGUS - associated neuropathy. The higher prevalence of 
neuropathy in patients with IgM MGUS may be related to 
the frequent reactivity of IgM M-proteins with myelin-
associated glycoprotein (MAG) [15]. Almost 50% of 
patients with IgM PDN have high titres of antibodies to 
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myelin- associated glycoprotein (MAG) , and this is the 
best defined syndrome of PDN, some other patients 
present IgM antibodies against different gangliosides. 
Most patients with IgM PDN have the “distal acquired 
demyelinating symmetrical” (DADS) clinical phenotype 
of predominantly distal, chronic (duration over 6 months), 
slowly progressive, symmetric, predominantly sensory 
impairment, with ataxia and relatively mild or no 
weakness, and often tremor. Testing for MAG-antibodies 
should be considered in all patients with IgM PDN. If 
negative, then testing for IgM antibodies against other 
neural antigens, including gangliosides GQ1b, GM1, 
GD1a and GD1b, and SGPG, may be considered [16]. 
Patients with IgG or IgA PDN usually have both 
proximal and distal weakness, with motor and sensory 
impairment. No specific antibody has been consistently 
associated with demyelinating neuropathy in patients with 
IgG or IgA paraprotein, so there is no need to test for 
serum antibodies to known neural epitopes in routine 
practice. 
Many patients are initially thought to have an 
ordinary PDN, until POEMS (Polyneuropathy, 
Organomegaly, Endocrinopathy, Monoclonal band and 
Skin changes) syndrome (Table 1) is suggested by the 
presence of systemic features such as sclerotic bone 
lesions, hepatosplenomegaly, lymphadenopathy, 
endocrinopathy, papilloedema, skin changes 
(hypertrichosis, hyperpigmentation, diffuse skin 
thickening, finger clubbing, dermal haemangiomas, white 
nail beds) and edema. 
POEMS usually has an underlying osteosclerotic 
myeloma, with IgA or IgG lambda paraprotein, or 
sometimes Castleman’s disease. 
Patients with PDN must be referred to the 
neurologist for the specific treatment (plasma exchange, 
intravenous immunoglobulin, corticosteroids, 
immunosoppressive therapies, interpheron-alpha, 
Rituximab) [17]. 
MGUS has confirmed and reported associations with 
numerous diseases that are commonly encountered in 
clinical practice, such as osteoporosis [18], dermatological 
diseases (Lichen myxoedematosus, scleroderma, 
pyoderma gangrenosum, necrobiotic xanthogranuloma, 
discoid lupus erythematosus, psoriasis, cutaneous 
lymphoma), rheumatologic diseases (rheumatoid arthritis, 
inflammatory seronegative polyarthritis, polymyositis, 
polymyalgia rheumatica, myasthenia gravis, angioneurotic 
edema) and liver diseases (chronic hepatitis, cirrhosis, 
primary biliary cirrhosis) [19]. AIDS and HIV infection, 
renal transplantation, bone marrow transplantation and 
many other conditions determining immunosuppression 
can be associated to MGUS. Recent observations suggest 
to also consider a form of MGUS of renal significance 
(MGRS) [18] as a growing number of kidney diseases 
which present with renal impairment and a nephrotic 
range proteinuria are associated to a MGUS-like clonal 
pasma cell disorder. The renal impairment seems to be 
misdiagnosed in this subgroup of patients, leading to a 
great deal of morbidity and even mortality [18]. From a 
practical point of view these data suggest in case of M-
protein detection and renal failure and/or proteinuria, not 
only a bone marrow aspirate to exclude MM, but also a 
kidney biopsy [18]. Among rare disorders, Gaucher 
disease can debut with the presence of a monoclonal 
gammopathy and anemia and it should be considered in 
the differential diagnosis of MGUS [21]. 
Venous thrombosis can also be associated to MGUS 
[19]. MGUS patients just like MM patients present an 
increased risk of Venous thromboembolic disease (VTD) 
and arterial thrombosis. There is no current evidence to 
explain this pre-thrombotic state; a high concentration of 
M-protein is linked to an increased risk for thrombosis, 
especially in patients with IgG or IgA MGUS [13,22,23]. 
While guidelines for prophylactic interventions in 
MM patients have been published [24] there is lack of a 
consensus about the management of MGUS patients. 
Studies published to date suggest to consider 
antithrombotic therapy for patients with IgG/IgA MGUS 
plus the presence of additional risk factors for thrombosis 
(age, obesity, inherited thrombophilia, history of VTE, 




III.  PATHOPHYSYOLOGY 
 
The etiology of MGUS remains unclear and is a 
current topic of investigation. Race and ethnicity seem to 
play a role in the pathogenesis as the prevalence of MGUS 
is 2- to 3-fold higher in African-Americans and blacks 
from Africa compared to whites. Advancing age, male 
sex, family history of haematologic malignancies, 
immunosuppression, and exposure to certain pesticides all 
increase the risk of MGUS [1,25- 29]. 
MGUS and smoldering multiple myeloma (SMM) 
are premalignant precursor tumors of MM that are stable 
and not associated with the presence of secondary clinical 
manifestations [30,31]. They both are derived from 
activated B- cells that have undergone several rounds of 
hypermutation and antigen selection in Germinal centers 
(GCs) and immunoglobulin heavy chain (IgH) switch 
recombination before differentiating into plasmoblasts 
(PBs). PBs from the GC migrate back to the bone marrow 
where they become terminally differentiated long-lived 
PCs. MGUS, SMM, and MM are monoclonal tumors that 
retain many of the phenotypic properties of healthy 
PBs/PCs but in contrast to their normal counterpart they 
maintain low proliferation rates that can increase 
markedly in late stages of MM [32,33].  
The pathophysiology of the transition from normal 
PCs to MGUS to multiple myeloma involves many 
overlapping oncogenic events [34] . 
The first step in the pathogenesis is usually an 
abnormal response to antigenic stimulation, possibly 
mediated by aberrant expression of toll-like receptors, 
overexpression of interleukin (IL) 6 receptors and IL-1β, 
and dysregulation of the cyclin D gene [4,35,36]. 
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The development of primary cytogenetic 
abnormalities (the most common are t(4;14), t(14;16), 
t(6;14), t(11;14), and t(14;20), hyperdiploidy or 
immunoglobulin heavy chain (IgH) translocations are 
likely followed by a random second hit such as Ras and 
p53 mutations, p16 methylation, myc abnormalities, and 
induction of angiogenesis. Finally, in most advanced 
stages, there is increased osteoblast RANKL (receptor 
activator of nuclear factor κB ligand) expression and 
reduction in the level of its decoy receptor, 
osteoprotegerin, which results in osteoclast activation and 
increased bone resorption and turnover [37]. This is 
accompanied by increased levels of IL-3, IL-7, and 
dickkopf 1 that simultaneously inhibit osteoblast 





IV. RISK STRATIFICATION MODELS 
 
At present, there are no reliable biologic markers that 
predict which individual with MGUS will progress to MM 
or related conditions. In the absence of such markers, 
MGUS is currently risk stratified based on clinical 
variables identified through epidemiological studies. 
Two predictive risk models for MGUS to MM have 
been developed by the Mayo Clinic and the Spanish study 
group investigators (PETHEMA). 
The Mayo Clinic model is centered on serum protein 
abnormalities and identifies 3 major risk factors for 
progression: non-IgG isotype, serum M-component 
concentration > 1.5 g/dL, and an abnormal FLC ratio. The 
FLC ratio is measured using a highly sensitive serum free 
light chain assay that quantitates free kappa (κ) and 
lambda (λ) chains secreted by PCs (normal range for free 
κ, 0.33 to 1.94 mg/dL; normal range for free λ, 0.57 to 
2.63 mg/dL).(41-42). The normal FLC ratio (free κ /free 
λ) is 0.26 to 1.65. (33) Patients with a serum FLC ratio < 
0.26 are defined as having monoclonal λ free light chain 
and those with ratios > 1.65 are defined as having a 
monoclonal κ free light chain (Table 1) [5]. 
Patients with an abnormal serum FLC ratio, non-IgG 
MGUS, and a high serum M protein level (≥1.5 g/dL) had 
a risk of progression of 58% at 20 years (high-risk 
MGUS), compared to 5% when none of the risk factors 
were present (low-risk MGUS)  (Table 2,3) [6]. 
The Spanish model uses multiparametric flow 
cytometry of BM aspirates to differentiate aberrant (aPCs) 
from normal PCs. PCs characteristically express CD138 
and intense (bright) CD38. The features of aPCs include 
decreased CD38 expression, expression of CD56, and the 
absence of CD19 and/or CD45. Risk factors for 
progression are ≥ 95% aPCs/BMPC and DNA aneuploidy 
[43]. 
Despite the existence of these significant predictive 
factors for progression, there are insufficient data on the 
preventative treatment of high-risk patients. In the future, 
additional markers may be added to risk stratification 
models to better define high-risk patients [44]. A small 
study, showed that PC phenotype (CD138/38/45 
expression) and sFLCs provide independent and 





V. THERAPEUTICAL STRATEGIES 
 
Although most people with MGUS die from 
unrelated illnesses, MGUS may transform into malignant 
monoclonal gammopathies. Patients should therefore be 
monitored on a regular basis to identify early signs of 
progression. 
Once MGUS is diagnosed primary care physicians 
will attend patients with M-protein < 15 g/L if IgG and 
patients with M-protein < 10 g/L if IgA or IgM, without 
end-organ damage and without signs and symptoms of 
LPD (lymphocitosis, thrombocytopenia, lymphadenopaty, 
hepatosplenomegaly, constitutional symptoms, 
hyperviscosity, unexplained heart failure, 
polyneuropathy). In case of IgM MGUS, the execution of 
a chest X-ray and an abdomen Echo tomography may be 
indicated. 
In June 2010, the International Myeloma Working 
Group (IMWG) released consensus guidelines for 
monitoring and managing patients with MGUS and 
smoldering myeloma. Patients with MGUS are divided 
into different categories based on low risk, intermediate 
risk, and high risk. If the serum monoclonal protein is 
<1.5 g/dL, IgG type, and the free light chain ratio is 
normal, then the risk of eventual progression to multiple 
myeloma or related malignancy is low [5].
 
TABLE III. RISK STRATIFICATION MODEL 
 
Number of factors Risk category 20 year progression risk (%) 
20 year progression risk accounting for 
death as competing factor (%) 
0 Low 5 2 
1 Low-intermediate 21 10 
2 High-intermediate 37 18 
3 High 58 27 
Source: see ref 11 
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In this low-risk setting, a baseline bone marrow 
examination or skeletal survey is not routinely indicated if 
the clinical evaluation and laboratory values suggest 
MGUS. Patients should be followed with SPEP 6 months 
after diagnosis and if stable can be followed every 2-3 
years (or sooner if symptoms suggestive of disease 
progression arise). Patients in the intermediate and high 
risk MGUS category are managed differently. They 
usually have a serum monoclonal protein >1.5 g/dL, IgA 
or IgM type, and/or an abnormal free light chain ratio. In 
this situation, a bone marrow biopsy should be carried out 
at baseline. Both conventional cytogenetics and 
fluorescence in situ hybridization should be performed. 
These patients are followed with SPEP, complete blood 
count, serum calcium and creatinine levels 6 months after 
diagnosis and then yearly for life. A bone marrow biopsy 
and skeletal survey is always indicated in patients with 
presumed MGUS with unexplained anemia, renal 
insufficiency, hypercalcemia, skeletal  lesion  or  in case  
of  increase of  the M-protein by more than 25% (a 






MGUS represents an interesting pre-malignant 
condition. Novel biomarkers, molecular profiles, and 
microenvironmental interactions of interest in 
myelomagenesis are being investigated to better 
understand the underlying mechanisms of its 
transformation to MM.  
Currently, in clinical practice, MGUS patients are 
followed without treatment until progression. In recent 
years, efforts to design models based on laboratory 
findings to evaluate the individual risk of progression 
have aimed to identify high- and low-risk patients for 
whom a tailored clinical management may let detect early 
signs of progression, and, possibly, its prevention or delay 
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